Correspondence

World Health Organization. Composite international diagnostic interview (CIDI) core version 2.0. Geneva: World Health Organization, 1996.

Adlaf EM Ivis FG Smart RG Alcohol and other drug use among Ontario adults in 1994 and changes since 1977. Toronto: Addiction Research Foundation, 1994.

Derogatis LR The symptom checklist 90-R: administration, scoring and procedures manual. 3rd ed. Minneapolis: National Computer Systems, 1994.

Brower KJ Eliopulos GA Blow GC Catlin DH Beresford TP Evidence for physical and psychological dependence on anabolic-androgenic steroids in eight weight lifters. American Journal of Psychiatry 1990; 147:510–512.

Brower KJ Blow FC Young JP Hill EM Symptoms and correlates of anabolic-androgenic steroid dependence. British Journal of Addiction 1991; 86:759–768.

Sawyer MG Meldrum D Tonge B Clark J. Mental health and young people. A report into the nature of mental health problems experienced by young people and implications for service provision. Hobart: National Clearing House for Youth Studies, 1992.

Patton G. An epidemiological case for a separate adolescent psychiatry. Australian and New Zealand Journal of Psychiatry 1996; 30:563–566.

Varma SL Zain AM Religion and spirituality. Australian and New Zealand Journal of Psychiatry 1997; 31:604–606.

Sher L. The placebo effect on mood and behaviour: the role of the endogenous opioid system. Medical Hypotheses 1997; 48:347–349.

Jevning R Wilson AF Vander-Laan EF Plasma prolactin and growth hormone during meditation. Psychosomatic Medicine 1978; 40:329–333.

Massion AO Teas J Hebert JR Wertheimer MD Kabat-Zinn J. Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. Medical Hypotheses 1995; 44:39–46.

MacLean CRK Walton KG Wenneberg SR Effects of the Transcendental Meditation program on adaptive mechanisms: changes in hormone levels and responses to stress after 4 months of practice. Psychoneuroendocrinology 1997; 22:277–295.

Kaplan HI Sadock BJ Grebb JA Kaplan and Sadock's synopsis of psychiatry: behavioural sciences, clinical psychiatry. 7th ed. Baltimore, MD: Williams and Wilkins, 1994.

Elias AN Wilson AF Serum hormonal concentrations following transcendental meditation —potential role of gamma-aminobutyric acid. Medical Hypotheses 1995; 44:287–291.

Essali MA Rezk E Wahlbeck K Cheine M. Clozapine vs ‘typical’ neuroleptic medication for schizophrenia. In: The Cochrane Database of Systematic Reviews [updated 04 March 1997].

Medelowicz A Stanton GL Alvir J Lieberman J. Clozapine-induced agranulocytosis: risk factors, monitoring and management. CNS Drugs 1995, 4/6:412–421.

Zyprexa product monograph. 29 April 1997: p. 10.

Risperdal product monograph. 14 March 1997.

Shoshani D Dorman P Lokshin P Clozapine-induced agranulocytosis: can olanzapine be a safer alternative? European Neuropharmacology 1997; 7(Suppl. 2):221.

Flynn SW Altman S Macewan GW Black LL Greenidge LL Honer WG Prolongation of clozapine-induced granulocytopaenia associated with olanzapine. Journal of Clinical Psychopharmacology 1977; 17:494–495.

Ellard J. Tests in psychiatry. Australian and New Zealand Journal of Psychiatry 1997; 31:808–811.